IL-BAI
19.8.2019 19:52:08 CEST | Business Wire | Press release
BAI announced the finalists for the 2019 BAI Global Innovation Awards, the industry’s most prestigious awards program that celebrates transformative solutions in the financial services industry worldwide.
Now in its ninth year, the BAI Global Innovation Awards recognizes leading financial services organizations on a global scale. Through hundreds of applications, the Innovation Circle , a panel of global financial services innovation leaders who thoroughly review each application, determined the top submissions.
The judges weigh each innovation on originality and impact on consumers and the industry. This year’s finalists showcase what leading financial services innovators in all regions of the world are doing to deliver new value to customers and employees, as well as improve efficiencies and profitability for their organizations.
The 2019 BAI Global Innovation Awards finalists are:
Best Application of Advanced Technology in a Product or Service
- Emirates NBD, Dubai, United Arab Emirates: Emirates NBD Blockchain Center of Excellence for Payments
- ISBANK, Istanbul, Turkey: AI Personal Assistant “Maxi”
- Shenzhen OneConnect Smart Technology Co., Ltd, Shanghai, China: FiMAX Trade Finance Blockchain Network
- Yapı Kredi, Istanbul, Turkey: Financial Document Corrective Analysis
Business Model Innovation
- CaixaBank S.A., Barcelona, Spain: Travel Marketplace
- DenizBank, Istanbul, Turkey: DenizBank Banking as a Platform Initiative
- KASIKORNBANK PCL, Bangkok, Thailand: K PLUS Loyalty Card Platform
- Royal Bank of Canada (RBC), Toronto, Canada: RBC Ventures
Human Capital Innovation
- Alior Bank S.A., Warsaw, Poland: Smartphonisation
- DenizBank, Istanbul, Turkey: Crowdfunding Platform, Fonosentez
- HDFC Bank, Mumbai, India: Recruitment Hackathon
- ISBANK, Istanbul, Turkey: Isbank Agile Atelier
- Ping An Insurance, Shenzhen, China: AI Interview System
Innovation in Customer Experience
- CaixaBank S.A., Barcelona, Spain: ATM Facial Recognition
- Commonwealth Bank of Australia, Sydney, Australia: Customer Experience Transformation via AI
- Emirates NBD, Dubai, United Arab Emirates: Customer Experience Month
- FNB Insurance, Johannesburg, South Africa: Claims Excellence
- The Bank of East Asia, Limited, Hong Kong: i-Planner
Innovation in Marketing
- CaixaBank S.A., Barcelona, Spain: imaginBank Agile Digital Marketing Room
- Elevate Credit, Fort Worth, Texas, U.S.: Elevate Credit Campaign 2019
- Fifth Third Bancorp, Cincinnati, Ohio, U.S.: Momentum Campaign
- ISBANK, Istanbul, Turkey: Maximum Gaming Esports Platform
- Pelican State Credit Union, Baton Rouge, Louisiana, U.S.: Pelican State of Mind
Innovation in Societal and Community Impact
- Absa Group Limited, Johannesburg, South Africa: Kongola
- BMO Harris Bank and Springfour, Chicago, Illinois, U.S.: BMO Harris - SpringFour Partnership
- JUMO.WORLD, Cape Town, South Africa: JUMO.WORLD
- Union Bank of the Philippines, Pasig, Philippines: Project i2i
Innovative Accelerator or Incubator
- Alior Bank S.A., Warsaw, Poland: RBL_START
- Citi Ventures, D10X, San Francisco, California, U.S.: D10X
- ISBANK, Istanbul, Turkey: Workup Entrepreneurship Program
- Royal Bank of Canada (RBC), Toronto, Canada: RBC Reach
- Woodforest National Bank, The Woodlands, Texas, U.S.: Woodforest Foundry
Innovative Touchpoints and Connected Experiences
- Aviva, Warsaw, Poland: Automated Claims Resolution Platform
- mBank S.A., Warsaw, Poland: Omni-channeling Asynchronous Chat
- Royal Bank of Canada (RBC), Toronto, Canada: DRIVE by RBC Ventures
Internal Process Innovation
- Alior Bank S.A., Warsaw, Poland: Smart Operations
- CommunityAmerica Financial Solutions, LLC, Lenexa, Kansas, U.S.: Dash360
- D10X, Citi, London, United Kingdom: Proxymity
- HDFC Bank, Mumbai, India: AI as a Service
- PKO Bank Polski, Warsaw, Poland: x-Platform
RegTech Innovation
- Hummingbird Regtech Inc, Walnut, California, U.S.: Regtech Solution
- Moody’s Analytics, San Francisco, California, U.S.: RiskFoundation™ Suite Hosted and Banking Cloud Solution
- Shenzhen OneConnect Smart Technology Co., Ltd, Shanghai, China: GAMMA Voiceprint Anti-fraud
- TSYS, Columbus, Georgia, U.S.: Foresight Score
- Yapı Kredi, Istanbul, Turkey: Digital Onboarding via Video Assistants
Congratulations to all the finalists of the BAI Global Innovation Awards. To learn more please visit BAIGlobalInnovations.com .
About BAI
As a nonprofit, independent organization, BAI delivers the financial services industry’s most actionable insights, enabling leaders to make smart business decisions every day. BAI is passionate about the trusted information and powerful tools that provide leaders with the clarity and confidence needed to drive positive change and move the financial services industry forward. For more information, visit www.bai.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190819005533/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom